Trial reportParasitology research2010
The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China.
Trial report in Parasitology research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Meta-analysis of the diagnostic efficiency of the questionnaires screening for schistosomiasis.Parasitology research · 2015Pooled it
- Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.Parasites & vectors · 2011Pooled it
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- New clinical application prospects of artemisinin and its derivatives: a scoping review.Infectious diseases of poverty · 2023Article
- New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China.Molecules (Basel, Switzerland) · 2014Review
- A review of dihydroartemisinin as another gift from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.Parasitology research · 2014Review
- Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum.Parasitology research · 2014Article
- Stem cell therapy for the treatment of parasitic infections: is it far away?Parasitology research · 2014Article
- Dihydroartemisinin: a new story of an old drug against Schistosoma mansoni infection.Parasitology research · 2014Article
- Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control.Parasitology research · 2012Article
- The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China?Parasitology research · 2012Article
- Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum.Parasitology research · 2011Article
- In-vivo activity of dihydroartemisinin against Schistosoma japonicum.Annals of tropical medicine and parasitology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis due to Schistosoma japonicum is a major public health problem in China. Since 1995, artesunate has been used to treat and prevent schistosome infections in China. Artesunate previously showed a high prophylactic efficacy against schistosome infection, with a protection rate of 100%. However, recent clinical trials and animal experiments have found that the sensitivity of many schistosomes to artesunate, including Schistosoma mekongi and Schistosoma mansoni, decreased. Whether the prophylactic efficacy of artesunate on Schistosomiasis japonica decreased after being used over 10-year period was still unknown. In the current study, we conducted a double-blind trial and found that the protection rate of artesunate was only 13.5% in the Administration I group, whose dosage schedule was identical to schedules used in previous studies. Therefore, the sensitivity of S. japonicum to artesunate was confirmed to have decreased after being using for over 10 years. Moreover, when we increased the concentration of artesunate during the first week and third week, the protection reached 74.8%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.